GLP-1 receptor agonists reduce sleep apnea severity by 14 events per hour

A systematic review and meta-analysis published in Sleep and Breathing has found that GLP-1 receptor agonists reduce the apnea-hypopnea index by nearly 14 events per hour in adults with obstructive sleep apnea and obesity. The same analysis reports 12.5 kg of weight loss and clinically meaningful reductions in both systolic and diastolic blood pressure.

Dandamudi and colleagues pooled data from four randomized controlled trials comparing GLP-1 receptor agonist therapy with placebo in adults with OSA. The meta-analysis, published April 24, is the most comprehensive synthesis to date of how this drug class affects sleep-disordered breathing beyond its established metabolic benefits.

The numbers

GLP-1 receptor agonists reduced the apnea-hypopnea index by a mean difference of 13.89 events per hour (p < 0.01). An AHI of 15 to 30 events per hour defines moderate OSA. A reduction of 14 points can move a patient from the moderate range into mild territory, or from severe to moderate. Body weight fell by 12.46 kg compared to placebo (p < 0.01). Systolic blood pressure dropped by 4.86 mmHg (p < 0.01). Diastolic blood pressure also fell significantly (p = 0.03).

A 5 mmHg reduction in systolic blood pressure at the population level corresponds to a roughly 10 percent lower risk of major cardiovascular events, based on the epidemiological benchmarks established by the 2002 PROGRESS meta-analysis in The Lancet. The cardiovascular benefit on top of the respiratory improvement is the finding that distinguishes this drug class from weight loss alone.

How it fits with the existing evidence

The 2024 SURMOUNT-OSA trials, led by Malhotra and published in the New England Journal of Medicine, had already shown that tirzepatide reduced AHI by 20.0 events per hour in patients not using positive airway pressure and by 23.8 events per hour in those using PAP. Those two phase 3 studies enrolled 469 participants and remain the largest trials in this space. Tirzepatide is a dual GIP/GLP-1 receptor agonist, which may explain why its effect sizes are larger than those seen with single-mechanism drugs.

A separate line of evidence comes from a meta-analysis presented at ATS 2025, covering six RCTs and 1,069 participants. That analysis reported a pooled AHI reduction of 10.0 events per hour. Broken out by agent, tirzepatide reduced AHI by 21.9 points and liraglutide by 5.7 points. The Dandamudi paper’s estimate of 13.9 points sits between those figures, consistent with a trial pool that includes both drugs.

The earliest signal came from a 2022 trial by Jiang and colleagues, also in Sleep and Breathing. The study found that liraglutide combined with CPAP reduced AHI and BMI more than CPAP alone in 90 patients with type 2 diabetes and severe OSA. The follow-up was short (3 months) and the effect sizes were modest by comparison with later tirzepatide data. But it established something important: GLP-1 receptor agonism was improving sleep-disordered breathing through mechanisms that went beyond weight loss alone.

What this means clinically

CPAP is the first-line treatment for moderate to severe OSA. It works when patients use it. The problem is that many don’t. Roughly 30 to 50 percent of patients stop using their machine within the first year. A pharmacological option that targets the metabolic drivers of OSA does not displace CPAP, but it offers an alternative when adherence breaks down or when obesity is the dominant contributor.

Weight loss is the clearest pathway. Excess fat in the neck and trunk increases pharyngeal collapsibility during sleep. Central adiposity compresses lung volumes when a person lies supine. A drug that sheds 12 kg should, on mechanical grounds alone, improve upper airway patency. But there is evidence that GLP-1 receptor agonists act on the respiratory system more directly. Nauck and colleagues, in a 2020 review in Molecular Metabolism, described GLP-1 receptors in brainstem regions that regulate breathing. The drug class may be doing two things at once: reducing the mechanical load through weight loss and modulating respiratory drive centrally.

Limits of the evidence

Four trials is not a lot. The meta-analysis is the most complete synthesis available, but the included studies differed in population (some enrolled only patients with type 2 diabetes), comparator (placebo in three, CPAP alone in one), and drug (tirzepatide and liraglutide). Heterogeneity in the AHI outcome was moderate. The paper did not provide a subgroup analysis by agent, so it is not possible to say whether the pooled benefit reflects a class effect or is carried by tirzepatide.

Tolerability matters in practice. GLP-1 receptor agonists cause nausea, vomiting, and diarrhoea in a substantial minority of patients. The SURMOUNT-OSA investigators described gastrointestinal adverse events as mostly mild to moderate, but more participants in the tirzepatide arm discontinued treatment. A patient who stops the drug for side effects gets none of the respiratory benefit.

There is also the question of who paid for the evidence. Eli Lilly funded the SURMOUNT-OSA trials. Lilly markets tirzepatide. The Dandamudi meta-analysis does not declare a pharmaceutical sponsor, but the individual trials it pools may carry industry funding. This is not a reason to dismiss the findings. It is a reason to read them with the usual caution.

Where the evidence stands

The Dandamudi meta-analysis does not rewrite the evidence base. It confirms a pattern that was already visible. The SURMOUNT-OSA trials, the ATS 2025 pooled analysis, the Jiang liraglutide trial, and now this synthesis all point to the same conclusion: GLP-1 receptor agonists reduce OSA severity, produce substantial weight loss, and lower blood pressure in patients who have both conditions. Tirzepatide produces the largest effect sizes by a wide margin.

No trial has yet randomized patients to GLP-1 receptor agonist versus CPAP versus the combination and followed them long enough to count cardiovascular events rather than AHI scores. That study would answer the question that matters most: whether pharmacological treatment of OSA changes hard outcomes. In its absence, the sensible clinical position is that GLP-1 receptor agonists are an adjunct, not a replacement for CPAP. Their clearest role is in patients whose sleep apnea is driven by obesity and who have not been able to sustain CPAP use.

References

1. Dandamudi M, Lucena L, Gamarra-Valverde NN, et al. Efficacy of GLP-1 receptor agonists in treating obstructive sleep apnea: a systematic review and meta-analysis of cardiometabolic and respiratory outcomes. Sleep and Breathing 30(2):138. 2026. https://doi.org/10.1007/s11325-026-03681-4
2. Malhotra A, Grunstein R, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. 2024. https://doi.org/10.1056/nejmoa2404881
3. Jiang WB, Li W, Cheng J, et al. Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep and Breathing. 2022. https://doi.org/10.1007/s11325-022-02768-y